SEC Company Response from Karyopharm Therapeutics Inc. (KPTI) (CIK 0001503802) (KPTI) — May 2, 2016
Karyopharm Therapeutics Inc. (KPTI) (CIK 0001503802)
Date: May 2, 2016 · CIK: 0001503802 · Accession: 0001193125-16-572593
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-201366
Letter
Karyopharm Therapeutics Inc.
85 Wells Avenue, 2nd Floor
Newton, MA 02459
May 2, 2016
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Karyopharm Therapeutics Inc.
Post-Effective Amendment No. 2 to Registration Statement on Form S-3
File No. 333-201366
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Karyopharm Therapeutics Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Post-Effective Amendment No. 2 to Registration Statement on Form S-3 (File No. 333-201366) (the “Registration Statement”), so that it may become effective at 4:00 p.m. Eastern Time on May 4, 2016, or as soon thereafter as practicable.
The Registrant hereby acknowledges that:
(i) should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement;
(ii) the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and
(iii) the Registrant may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Very truly yours,
KARYOPHARM THERAPEUTICS INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Karyopharm Therapeutics Inc. 85 Wells Avenue, 2nd Floor Newton, MA 02459 May 2, 2016 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Karyopharm Therapeutics Inc. Post-Effective Amendment No. 2 to Registration Statement on Form S-3 File No. 333-201366 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Karyopharm Therapeutics Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Post-Effective Amendment No. 2 to Registration Statement on Form S-3 (File No. 333-201366) (the “Registration Statement”), so that it may become effective at 4:00 p.m. Eastern Time on May 4, 2016, or as soon thereafter as practicable. The Registrant hereby acknowledges that: (i) should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement; (ii) the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and (iii) the Registrant may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. Very truly yours, KARYOPHARM THERAPEUTICS INC. By: /s/ Christopher B. Primiano Christopher B. Primiano Senior Vice President, Corporate Development, General Counsel and Secretary